Efficacy of Choleretics in Acalculous Gallbladder in Situ After Endoscopic Removal of Biliary Stones
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01829139|
Recruitment Status : Recruiting
First Posted : April 11, 2013
Last Update Posted : April 11, 2013
|Condition or disease|
|Common Bile Duct Stones Gallbladder in Situ Choleretics Biliary Complications|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||200 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||A Prospective Multicenter Comparative Study for Efficacy of Choleretics in Acalculous Gallbladder in Situ After Endoscopic Removal of Biliary Stones|
|Study Start Date :||March 2012|
|Estimated Primary Completion Date :||February 2014|
|Estimated Study Completion Date :||December 2021|
After endoscopic clearance of their bile duct stones, this group of patients will be follow up without additional managements
After endoscopic clearance of their bile duct stones, this group of patients receives choleretic agents during 3 months
- Complications [ Time Frame: two year ]The primary outcome is biliary complications between two groups during follow-up.
- Natural outcomes [ Time Frame: two year ]Other outcome measures included adverse events after choleretics and natural clinical courses of gallbladder in situ.
- Other adverse events [ Time Frame: two year ]Other outcome measures included adverse events after choleretics and natural outcomes of gallbladder in situ.
- Drug-related adverse event [ Time Frame: three months ]Other outcome measure includes adverse events after choleretics.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01829139
|Contact: Tae Hoon Lee, MD, PhDemail@example.com|
|Korea, Republic of|
|Soon Chun Hyang University Cheonan Hospital||Recruiting|
|Cheonan, Chungcheongnam-do, Korea, Republic of, 330-721|
|Contact: Tae Hoon Lee, MD, PhD|
|Principal Investigator: Tae Hoon Lee, MD, PhD|